News | August 05, 2021
Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Innovative solutions and a deep understanding of the market makes this a unique combination
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
Complementary business models are the reason for the acquisition
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company is confident of commencing production at both Mahad and Chiplun units soon
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Subscribe To Our Newsletter & Stay Updated
